BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 25522000)

  • 1. Characterization of the physical stability of a lyophilized IgG1 mAb after accelerated shipping-like stress.
    Telikepalli S; Kumru OS; Kim JH; Joshi SB; O'Berry KB; Blake-Haskins AW; Perkins MD; Middaugh CR; Volkin DB
    J Pharm Sci; 2015 Feb; 104(2):495-507. PubMed ID: 25522000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stability of lyophilized sucrose formulations of an IgG1: subvisible particle formation.
    Davis JM; Zhang N; Payne RW; Murphy BM; Abdul-Fattah AM; Matsuura JE; Herman AC; Manning MC
    Pharm Dev Technol; 2013; 18(4):883-96. PubMed ID: 22813478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Product and process understanding to relate the effect of freezing method on glycation and aggregation of lyophilized monoclonal antibody formulations.
    Awotwe-Otoo D; Agarabi C; Read EK; Lute S; Brorson KA; Khan MA
    Int J Pharm; 2015 Jul; 490(1-2):341-50. PubMed ID: 25835267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic investigation of the effect of lyophilizate collapse on pharmaceutically relevant proteins III: collapse during storage at elevated temperatures.
    Schersch K; Betz O; Garidel P; Muehlau S; Bassarab S; Winter G
    Eur J Pharm Biopharm; 2013 Oct; 85(2):240-52. PubMed ID: 23727369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a microflow digital imaging assay to characterize protein particulates during storage of a high concentration IgG1 monoclonal antibody formulation.
    Wuchner K; Büchler J; Spycher R; Dalmonte P; Volkin DB
    J Pharm Sci; 2010 Aug; 99(8):3343-61. PubMed ID: 20229596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Probing the Conformation of an IgG1 Monoclonal Antibody in Lyophilized Solids Using Solid-State Hydrogen-Deuterium Exchange with Mass Spectrometric Analysis (ssHDX-MS).
    Moussa EM; Singh SK; Kimmel M; Nema S; Topp EM
    Mol Pharm; 2018 Feb; 15(2):356-368. PubMed ID: 29355022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stability Studies of a Freeze-Dried Recombinant Human Epidermal Growth Factor Formulation for Wound Healing.
    Santana H; García G; Vega M; Beldarraín A; Páez R
    PDA J Pharm Sci Technol; 2015; 69(3):399-416. PubMed ID: 26048746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Formulation development of lyophilized, long-term stable siRNA/oligoaminoamide polyplexes.
    Kasper JC; Troiber C; Küchler S; Wagner E; Friess W
    Eur J Pharm Biopharm; 2013 Oct; 85(2):294-305. PubMed ID: 23747745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Compatibility, physical stability, and characterization of an IgG4 monoclonal antibody after dilution into different intravenous administration bags.
    Kumru OS; Liu J; Ji JA; Cheng W; Wang YJ; Wang T; Joshi SB; Middaugh CR; Volkin DB
    J Pharm Sci; 2012 Oct; 101(10):3636-50. PubMed ID: 22733600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure, stability, and mobility of a lyophilized IgG1 monoclonal antibody as determined using second-derivative infrared spectroscopy.
    Murphy BM; Zhang N; Payne RW; Davis JM; Abdul-Fattah AM; Matsuura JE; Herman AC; Manning MC
    J Pharm Sci; 2012 Jan; 101(1):81-91. PubMed ID: 21918984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Excipients for Room Temperature Stable Freeze-Dried Monoclonal Antibody Formulations.
    Haeuser C; Goldbach P; Huwyler J; Friess W; Allmendinger A
    J Pharm Sci; 2020 Jan; 109(1):807-817. PubMed ID: 31622600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The improved dissolution and prevention of ampoule breakage attained by the introduction of pretreatment into the production process of the lyophilized formulation of recombinant human Interleukin-11 (rhIL-11).
    Hirakura Y; Kojima S; Okada A; Yokohama S; Yokota S
    Int J Pharm; 2004 Nov; 286(1-2):53-67. PubMed ID: 15501002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The formation and effect of mannitol hemihydrate on the stability of monoclonal antibody in the lyophilized state.
    Anko M; Bjelošević M; Planinšek O; Trstenjak U; Logar M; Ahlin Grabnar P; Brus B
    Int J Pharm; 2019 Jun; 564():106-116. PubMed ID: 30999044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drying-induced variations in physico-chemical properties of amorphous pharmaceuticals and their impact on stability (I): stability of a monoclonal antibody.
    Abdul-Fattah AM; Truong-Le V; Yee L; Nguyen L; Kalonia DS; Cicerone MT; Pikal MJ
    J Pharm Sci; 2007 Aug; 96(8):1983-2008. PubMed ID: 17286290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating the Role of the Air-Solution Interface on the Mechanism of Subvisible Particle Formation Caused by Mechanical Agitation for an IgG1 mAb.
    Ghazvini S; Kalonia C; Volkin DB; Dhar P
    J Pharm Sci; 2016 May; 105(5):1643-1656. PubMed ID: 27025981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of moisture on the stability of a lyophilized humanized monoclonal antibody formulation.
    Breen ED; Curley JG; Overcashier DE; Hsu CC; Shire SJ
    Pharm Res; 2001 Sep; 18(9):1345-53. PubMed ID: 11683251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Effects of Excipients on Freeze-dried Monoclonal Antibody Formulation Degradation and Sub-Visible Particle Formation during Shaking.
    Jin MJ; Ge XZ; Huang Q; Liu JW; Ingle RG; Gao D; Fang WJ
    Pharm Res; 2024 Feb; 41(2):321-334. PubMed ID: 38291165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of pH and excipients on structure, dynamics, and long-term stability of a model IgG1 monoclonal antibody upon freeze-drying.
    Park J; Nagapudi K; Vergara C; Ramachander R; Laurence JS; Krishnan S
    Pharm Res; 2013 Apr; 30(4):968-84. PubMed ID: 23184227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality by design: impact of formulation variables and their interactions on quality attributes of a lyophilized monoclonal antibody.
    Awotwe-Otoo D; Agarabi C; Wu GK; Casey E; Read E; Lute S; Brorson KA; Khan MA; Shah RB
    Int J Pharm; 2012 Nov; 438(1-2):167-75. PubMed ID: 22944306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Freeze drying of L-arginine/sucrose-based protein formulations, part I: influence of formulation and arginine counter ion on the critical formulation temperature, product performance and protein stability.
    Stärtzel P; Gieseler H; Gieseler M; Abdul-Fattah AM; Adler M; Mahler HC; Goldbach P
    J Pharm Sci; 2015 Jul; 104(7):2345-58. PubMed ID: 25994980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.